Therapy News and Research

RSS

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced that the U.S. Food and Drug Administration has assigned a Priority Review designation to the supplemental New Drug Application for the use of ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for the first-line treatment of patients with advanced pancreatic cancer.

23 May 2013

Arthritis Research UK awards Cardiff researchers a grant to develop new drugs to treat osteoarthritis

Medical research charity Arthritis Research UK has awarded a team of researchers at Cardiff University a grant of £200,000 to investigate new drugs to treat early onset osteoarthritis. The team will investigate a new therapy to reduce the risk of developing osteoarthritis.

23 May 2013

CardioKinetix reports meta-analysis study results of Parachute Ventricular Partitioning Device

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced results of a meta-analysis study of the first-of-its-kind catheter-based Parachute Ventricular Partitioning Device. Six-month clinical results from 91 U.S. and European patients with ischemic heart failure were presented at the 2013 EuroPCR Conference in Paris by Dr. Martyn Thomas, M.D., chairman of Cardiology at St. Thomas Hospital in London, England.

23 May 2013

Johns Hopkins researchers find possible trigger of rheumatoid arthritis

In a series of lab experiments designed to unravel the workings of a key enzyme widely considered a possible trigger of rheumatoid arthritis, researchers at Johns Hopkins have found that in the most severe cases of the disease, the immune system makes a unique subset of antibodies that have a disease-promoting role.

23 May 2013

$Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS$

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

Upsher-Smith Laboratories, Inc. today announced the successful completion of its global Phase III clinical trial for USL255 (extended-release topiramate), an internally developed program for the management of epilepsy in adults, using the company's proprietary formulation technology.

23 May 2013

Physicists demonstrate effect of cold atmospheric plasma, chemo therapy on brain tumour cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.

23 May 2013

Cancer experts to discuss latest developments and implications of cell therapies in oncology

John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 cancer centers, will bring together leading cancer experts, for presentation and discussion of the latest developments and implications of cell therapy and interventional immunology in oncology, on Friday, June 7 from 7:00am to 1:30pm.

23 May 2013

Researchers find that over 40% of patients treated for COPD did not actually have the disease

More than 40 percent of patients being treated for COPD at a federally funded clinic did not have the disease, researchers found after evaluating the patients with spirometry, the diagnostic "gold standard" for chronic obstructive pulmonary disease.

23 May 2013

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

Northwestern University researchers have developed a new method for delivering molecules into single, targeted cells through temporary holes in the cell surface. The technique could find applications in drug delivery, cell therapy, and related biological fields.

22 May 2013

A1-PI treatment slows progression of emphysema in patients with AATD

Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic disorder, according to a new study presented at the 2013 American Thoracic Society International Conference.

22 May 2013

Mayo Clinic expert offers tips for children with weather-related fears

Violent storms — often accompanied by lightning, thunder, heavy rain, powerful winds and even tornado warnings — can be stressful for anyone, but severe weather can trigger much more severe anxiety, especially among children.

22 May 2013

Obesity directly tied to several cancers

"Obesity is a major risk factor for developing cancer, roughly the equivalent of tobacco use, and both are potentially reversible. Further, obese cancer patients do worse in surgery, with radiation or on chemotherapy - worse by any measure." Karen Basen-Engquist, Ph.D., Director of MD Anderson's new Center for Energy Balance in Cancer Prevention and Survivorship and professor of Behavioral Science.

22 May 2013

FAPESP funds $680 million to support 17 RIDCs

The Brazilian funding agency for scientific and technological research S-o Paulo Research Foundation, FAPESP, based in the state of S-o Paulo, announced an investment estimated in US$ 680 million to support 17 Research, Innovation and Dissemination Centers for a period of up to eleven years, subject to continuation reviews on years 2, 4 and 7.

22 May 2013

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, less expensive forms of radiation therapy in patients who have had a prostatectomy.

22 May 2013

Study reinforces efficacy of NeuroStar TMS Therapy System in patients with MDD

New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder during the acute phase of therapy, which were maintained through one year of treatment.

22 May 2013

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

PuraMed BioScience, Inc., a researcher, developer, and marketer of over-the-counter medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic M, has "robust efficacy".

22 May 2013

AIR2 trial: Alair BT System shows therapy benefits in adults with severe uncontrolled asthma

Five-year data from the Asthma Intervention Research 2 clinical trial presented today demonstrated that the Boston Scientific Corporation Alair Bronchial Thermoplasty System continues to show therapy benefits in adult patients with severe uncontrolled asthma.

22 May 2013

Gilead Sciences' sofosbuvir MAA gets EMA validation

Gilead Sciences, Inc. today announced that the company's Marketing Authorisation Application for sofosbuvir, a once-daily oral nucleotide analogue inhibitor for the treatment of chronic hepatitis C virus infection, which was submitted to the European Medicines Agency on April 17, 2013, has been fully validated and is now under assessment.

22 May 2013

Researchers make gold nanoparticles more effective against ovarian cancer cells

Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells.

22 May 2013

Experts develop new guidelines for safe and effective use of anticoagulants

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, account for nearly 7 percent of medication errors in hospitalized patients.

22 May 2013

Therapy News and Research

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer

Arthritis Research UK awards Cardiff researchers a grant to develop new drugs to treat osteoarthritis

CardioKinetix reports meta-analysis study results of Parachute Ventricular Partitioning Device

Johns Hopkins researchers find possible trigger of rheumatoid arthritis

Upsher-Smith completes USL255 Phase III clinical trial in patients with refractory POS

Physicists demonstrate effect of cold atmospheric plasma, chemo therapy on brain tumour cells

Cancer experts to discuss latest developments and implications of cell therapies in oncology

Researchers find that over 40% of patients treated for COPD did not actually have the disease

Researchers develop new method for delivering molecules into targeted single cells through temporary holes

A1-PI treatment slows progression of emphysema in patients with AATD

Mayo Clinic expert offers tips for children with weather-related fears

Obesity directly tied to several cancers

FAPESP funds $680 million to support 17 RIDCs

Research suggests that IMRT may not be more effective in patients who had prostatectomy

Study reinforces efficacy of NeuroStar TMS Therapy System in patients with MDD

Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

AIR2 trial: Alair BT System shows therapy benefits in adults with severe uncontrolled asthma

Gilead Sciences' sofosbuvir MAA gets EMA validation

Researchers make gold nanoparticles more effective against ovarian cancer cells

Experts develop new guidelines for safe and effective use of anticoagulants

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News